Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NTR-1011 will be presented as a solution for intravenous (IV) administration.”In the company’s words, NCT07237659 on ClinicalTrials.gov
- Tested for
- SLE (Systemic Lupus), RA - Rheumatoid Arthritis
- Main trialPhase 1
- “The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). It will also learn about the safety of NTR-1011 in healthy adult volunteers. The main questions it aims to answer are: * What is the highest dose of NTR-1011 that is safe and well tolerated, when given under the skin or into a vein? * How does the body process NTR-1011, and how does NTR-1011 affect the body? * Does the body develop an immune response to NTR-1011? * Are there early signs that NTR-1011…”In the company’s words, NCT07237659 on ClinicalTrials.gov
Other drugs for SLE (Systemic Lupus)
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
Coming up1
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Mar 2027 | Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026